Table 2b.
Demographic and Clinical Characteristics of Heart and Lung Transplant Recipients With Stratification by Antibody Response to a Two-Dose Course of SARS-CoV-2 Messenger RNA vaccine
| LT recipient vaccine response, No. (%) |
|||
|---|---|---|---|
| Priming dose responders | Booster responders | Non-responders | |
| n = 9 | n = 28 | n = 66 | |
| Age group, y | |||
| 18–39 | 3 (19) | 2 (12) | 11 (69) |
| 40–59 | 1 (4) | 11 (41) | 15 (55) |
| ≥60 | 5 (8) | 15 (25) | 40 (67) |
| Sexa | |||
| Male | 4 (10) | 14 (34) | 23 (56) |
| Female | 5 (8) | 13 (22) | 42 (70) |
| Raceb | |||
| White | 9 (10) | 24 (25) | 62 (65) |
| Non-white | 0 (0) | 3 (50) | 3 (50) |
| Time since transplant, y | |||
| <3 | 1 (3) | 10 (28) | 25 (69) |
| 3-6 | 4 (12) | 7 (21) | 22 (67) |
| 7-11 | 2 (11) | 5 (28) | 11 (61) |
| ≥12 | 2 (13) | 6 (37) | 8 (50) |
| Type of regimen | |||
| Includes anti-metabolite maintenance immunosuppressionc | 6 (8) | 19 (25) | 52 (68) |
| Does not include anti-metabolite maintenance immunosuppression | 3 (12) | 9 (34) | 14 (54) |
| Vaccine | |||
| mRNA-1273 (Moderna) | 5 (10) | 13 (28) | 29 (62) |
| BNT16b2 (Pfizer-BioNTech) | 4 (7) | 15 (27) | 37 (66) |
LT, Lung transplant.
a
Missing data for 2 participants.
b
Missing data for 2 participants.
c
Antimetabolite maintenance immunosuppressive regimens included mycophenolate mofetil, mycophenolic acid, and azathioprine.